drugset / Trial / NCT06600321
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT as monotherapy and in combination with pembrolizumab. The purpose of the dose expansion part of the of the study is to evaluate the antitumor activity of ALN-BCAT as monotherapy and in combination with pembrolizumab; to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab.
Timeline
- Start
- 2024-12-30
- Primary completion
- 2027-09-30
- Completion
- 2027-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALN-BCAT | Unknown | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |